期刊文献+

脾源性酪氨酸激酶抗肿瘤侵袭迁移的作用机制 被引量:1

The mechanism underlying the inhibitory effect of spleen tyrosine kinase on the invasion and migration of human breast cancer cells
下载PDF
导出
摘要 目的:研究脾源性酪氨酸激酶(spleen tyrosine kinase,Syk)抗人乳腺癌肿瘤细胞的侵袭迁移能力,并对其作用机制进行初步探讨。方法:将全长SykcDNA经脂质体介导转染Syk表达阴性的高侵袭性人乳腺癌细胞MDA-MB-231,Transwell小室法检测转染前后肿瘤细胞侵袭迁移能力的变化,流式细胞术及酶联免疫吸附测定法检测与侵袭转移相关的血管内皮生长因子和基质金属蛋白酶-9的表达情况。结果:转染Syk全长基因的MDA-MB-231细胞与转染空载体及未转染的MDA-MB-231细胞相比,侵袭及迁移实验中的穿膜细胞数(总迁移细胞数/5个高倍视野)均明显减少(P<0.05);血管内皮生长因子及基质金属蛋白酶-9的表达量亦明显减少(P<0.05)。结论:转染SykcDNA可通过降低转染肿瘤细胞血管内皮生长因子及基质金属蛋白酶-9的表达,参与其抗肿瘤侵袭迁移作用。 Objective:To investigate the effect of spleen tyrosine kinase (Syk) on invasion and migration in human breast cancer cells and analyze its action mechanism. Methods. Full-length cDNA of Syk was transfected into Syk-negative human breast cancer cells MDA-MB-231 via liposome mediation. The invasion and migration ability of MDA-MB-231 cells was detected by Transwell ECM method. The expressions of invasion and migration-related molecule vasculars, endothelial growth factor (VEGF) and matrix metalloproteinaseses- 9 ( MMP-9), were detected by flow cytometry (FCM) and enzyme-linked immunosorbant assy (ELISA) methods. Results:The number of membrane-passing cells every 5 high power fields was significantly decreased in Syk-transfected MDA-MB-231 cells compared with those transfected with blank vector or without transfection ( P 〈 0.05 ) . The expressions of VEGF and MMP-9 proteins were obviously reduced (P 〈 0.05). Conclusion:Syk cDNA inhibited the invasion and migration of tumor cells by down-regulating the expressions of VEGF and MMP-9.
出处 《肿瘤》 CAS CSCD 北大核心 2008年第7期548-551,共4页 Tumor
基金 河北省科学技术研究与发展计划资助项目(编号05276101D-73) 河北省普通高校强势特色学科建设资助项目(编号:冀教高[2005]52号)
关键词 蛋白质酪氨酸激酶 乳腺肿瘤 肿瘤浸润 肿瘤转移 基因表达 Protein-spleen tyrosine kinase Breast neoplasms Neoplasm invasiveness Neoplasm metastasis Gene expression
  • 相关文献

参考文献13

  • 1COOPMAN P J, DO MT, BARTH M, et al. The Syk tyrosine kinase suppresses malignant growth of human breast cancer cells [ J ]. Nature, 2000,406 (6797) :742-747.
  • 2齐义新,胡洁,宋振川,董青,单保恩.Syk mRNA在浸润性乳腺癌组织中的表达及其临床意义[J].肿瘤,2005,25(5):475-477. 被引量:2
  • 3TOYAMA T, IWASE H, YAMASHITA H, et al. Reduced expression of the Syk gene is correlated with poor prognosis in human breast cancer[ J]. Cancer Lett, 2003 , 189( 1 ) :97-102.
  • 4KOCHETKOVA M, MCKENZIE O L, BAIS A J, et al. CBFA2T3 (MTG16) is a putative breast tumor suppressor gene from the breast cancer loss of heterozygosity region at 16q24.3 [ J]. Cancer Res ,2002,62 ( 16 ) :4599-4604.
  • 5WOLF I, O' KELLY J, RUBINEK T,et al. 15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer [ J ]. Cancer Res,2006,66( 15 ) :7818-7823.
  • 6KUMAR R, NEILSEN PM, CRAWFORD J, et al. FBXO31 is the chromosome 16q24. 3 senescence gene, a candidate breast tumor suppressor, and a component of an SCF complex [ J ]. Cancer Res ,2005,65 ( 24 ) : 11304-11313.
  • 7BEDNAREK A K, KECK-WAGGONER C L, DANIEL R L, et al. WWOX, the FRA16D gene, behaves as a suppressor of tumor growth[J]. Cancer Res,2001,61( 22 ) :8068-8073.
  • 8NUNEZ M I, LUDES-MEYERS J, ABBA M C, et al. Frequent loss of WWOX expression in breast cancer: correIation with estrogen receptor status[J]. Breast Cancer Res Treat,2005,89(2) :99- 105.
  • 9KROP I, MAGUIRE P, LAHTI-DOMENICI J, et al. HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells[ J]. Proc Natl Acad Sci U S A ,2001,98 ( 17 ) :9796-9801.
  • 10KROP I, PARKER MT, BLOUSHTAIN-QIMRON N, et al. HIN- 1, an inhibitor of cell growth, invasion, and AKT activation[ J]. Cancer Res ,2005,65 ( 21 ) :9659-9669.

二级参考文献6

  • 1Turner M, Schweighoffer E,Colucei F, et al. Tyrosine kinase Syk, essential functions for immunoreceptor signaling[J]. Immunol Today,2000, 21: 148-154.
  • 2Tatsuya Toyama, Hirotake Lwase, Hiroko Yamashita, et al. Reduced expression of the Syk gene is correlated with poor prognosis in human breast cancer[J]. Science, 2003,189:97-102.
  • 3Fluck M, Zurcher G, Andres AC,et al. Molecular characterization of the murine Syk protein tyrosine kinase cDNA, transcripts and protein[J]. Biochem Biophys Res Commun,1995,213 : 273-281.
  • 4Brunner N, Thompson EW,Spang-Thomsen M, et al. LacZ transduced human breast cancer xenografts as an in vivo model for the study of invasion and metastasis[J]. Eur J Cancer,1992,28A(12) : 1989-1995.
  • 5Jiang A, Craxton A, Kurosaki T, et al. Different protein tyrosine kinases are required for B cell antigen receptor mediated activation of extracellular signal-regulated kinase, c-Jun NH2-terminal kinase 1, and p38 mitogen-activated protein kinase[J]. J Exp Med, 1998,188:1297-1306.
  • 6Coopman PJP,Domt H, Barth M, et al. The Syk tyrosine kinase suppresses malignant growth of human breast cancer cells[J]. Nature, 2000, 406 : 742-747.

共引文献1

同被引文献13

  • 1常城,孔佩艳,陈幸华,彭贤贵,刘林,刘红,曾东风,梁雪,王庆余.钠氢交换蛋白-1特异性抑制剂二甲基氨氯吡咪对HL-60/ADM细胞pHi变化及细胞增殖、凋亡的影响[J].中国实验血液学杂志,2006,14(3):488-491. 被引量:6
  • 2LI Y Y, LIANG N C, JIANG L. Dimethyl amiloride-induced differentiation of HL-60 cells [J]. Acta Pharmacol Sin, 2000, 21 ( 5 ) :445-449.
  • 3HELENIUS M A, SAVINAINEN K J, BOVA G S, et al. Amplification of the urnkinase gene and the sensitivity of prostate cancer cells to urokinase inhibitors [J]. BJU lnt, 2006, 97 ( 2 ) : 404- 409.
  • 4EVANS D M, SLOAN-STAKLEFF K. Suppression of the invasive capacity of human breast cancer cells by inhibition of urokinase plasminogen activator via amiloride and B428 [J]. Am Surg, 2000, 66(5) :460-464.
  • 5FRUEH F W, HAYASHIBARA K C, BROWN P O, et al. Use of cDNA mieroarrays to analyze dioxin-indueed changes in human liver gene expression[J]. Toxicol Lett, 2001, 122(3) : 189-203.
  • 6DE PETRO G, TAVIAN D, COPETA A, et al. Expression of urokinase-type plasminogen activalor ( u-PA ), u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma [J]. Cancer Res, 1998, 58(10) : 2234-2239.
  • 7TAKAHASHI T, SUZUKI K, IHARA H, et al. Plasminogen activalor inhibitor type 1 promotes fibrusarcoma cell migration by modifying cellular attachment to vitronectin via alpha(v) beta(5) integrin[J]. Semin Thromb Hemost, 2005, 31 ( 3 ) :356-363.
  • 8SALDEN M, SPLINTER T A, PETERS H A, et al. The urokinase-type plasminogen activator system in resected non-small-cell lung cancer. Rotterdam Oncology Thoracic Study Group [J]. Ann Oncol, 2000, 11 ( 3 ) :327-332.
  • 9LIU G, SHUMAN M A, COHEN R L. Co-expression of urokinase, urokinase receptor and PAI-1 is necessary fur optimum invasiveness of cuhured lung cancer cells[J]. Int J Concer, 1995,60 (4): 501-506.
  • 10SUBRAMANIAN R, GONDI C S, LAKKA S S, et al. siRNA-mediated simultaneous downregulation of uPA and its receptor inhibits angiogenesis and invasiveness triggering apoptosis in breast cancer cells[J]. Int J Oncol, 2006, 28(4) :831-839.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部